Alpha Lipoic Acid: MD Anderson: google.com/url... - CLL Support
Alpha Lipoic Acid: MD Anderson
Kevin, unfortunately the trial was several years ago and the following is the results.
(When you look at a Clinical Trial, look for the dates the trial was administered and is expected to end).
Results: Seventy of 243 (29 %) patients completed the study (24 weeks). Both the ALA and the placebo arms had a comparable drop-out rate. No statistically significant differences were found between the ALA and the placebo groups for FACT/GOG-Ntx scores, BPI scores, and patients' functional outcomes.
Conclusion: This strategy of oral ALA administration was ineffective at preventing neurotoxicity caused by oxaliplatin or cisplatin. High attrition rates due to poor patient compliance and manner of dosage administration in this trial demonstrated a lack of feasibility for this intervention. Future studies to explore ALA as a neuroprotective agent should take heed of the barriers confronted in this study.